Reversing Therapy Resistance With Epigenetic-Immune Modification
Reversing Therapy Resistance With Epigenetic-immune Modification: Phase II Trial of Vorinostat, Tamoxifen and Pembrolizumab in Hormone Receptor Expressing Advanced Breast Cancer
Sponsor: Avon Foundation
Terminated
Insufficient efficacy in an unselected patient population
Other terminated trials from Avon Foundation
Other Breast Neoplasms trials with similar outcome
A PHASE2 clinical study on Breast Neoplasms, this trial is terminated or withdrawn. The trial is conducted by Avon Foundation and has accumulated 10 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jun 2022 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 5 earlier versions
-
Aug 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2019 — Aug 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
May 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Avon Foundation
- Merck Sharp & Dohme LLC
- University of California, San Francisco
For direct contact, visit the study record on ClinicalTrials.gov .